Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy

Abstract Background While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventio...

Full description

Bibliographic Details
Main Authors: John Anderson, Donald S. Levy, William Lumry, Patricia Koochaki, Sally Lanar, H. Henry Li
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Online Access:https://doi.org/10.1186/s13223-021-00550-5
id doaj-aed4064836e946e98087be2e6fa6d3c6
record_format Article
spelling doaj-aed4064836e946e98087be2e6fa6d3c62021-07-04T11:48:13ZengBMCAllergy, Asthma & Clinical Immunology1710-14922021-06-0117111310.1186/s13223-021-00550-5Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapyJohn Anderson0Donald S. Levy1William Lumry2Patricia Koochaki3Sally Lanar4H. Henry Li5Clinical Research Center of AlabamaUC IrvineAARA Research CenterICONICONInstitute for Asthma and AllergyAbstract Background While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventional, qualitative research study was designed to investigate the reasons for improvements in HRQoL while using effective prophylaxis, in this case subcutaneous C1INH (C1INH[SC]) replacement therapy. Methods Adult patients with HAE-C1INH type 1 or 2 who had been using C1INH(SC) for ≥ 3 consecutive months were recruited through four HAE specialty practices in the US to participate in a 60-min phone interview performed by a trained qualitative research specialist (ICON plc) using a semi-structured interview guide with open-ended questions developed with the Angioedema Quality of Life (AE-QoL) items in mind. Interview transcripts were analyzed using thematic analysis methods to identify concepts (specific symptoms/impacts) and themes (higher-level categories grouping related concepts). A cross-mapping exercise was performed between interview-identified concepts and items included in the AE-QoL. Results Fourteen patients were interviewed and included in the analysis (age range, 28–82 years [mean 47.5 years]; 64% female; 93% white). In 10 interviews, patients mentioned having no or nearly no HAE attacks, no longer feeling limited by HAE, less HAE-related anxiety/worry and depression, an improved ability to travel, fewer emergency room/hospital visits, and ease of administration of C1INH(SC), including not requiring assistance from others. Other commonly expressed concepts included: increased feelings of confidence, independence, optimism, and normalcy; less absence from work/school; better productivity; improved sleep and energy; healthier family relationships; and improved cognition. While all AE-QoL items emerged from patient interviews, a number of identified concepts were not addressed by the AE-QoL, including sensitivity to various potential attack-triggers (e.g., stress/anxiety, sports), attack frequency, not having to cancel social plans, improvements in ability to perform day-to-day tasks, and a lower burden from medical visits. Conclusions From these interviews, a large number of common themes and concepts emerged: a greater sense of freedom and normalcy, increased productivity, and improved interpersonal relationships while using convenient and effective prophylaxis. These findings provide insights into real-world experiences and the many facets of HRQoL that are important to patients with HAE-C1INH.https://doi.org/10.1186/s13223-021-00550-5Subcutaneous C1-inhibitorHereditary angioedemaHealth-related quality of lifeProductivityHAEGARDAQualitative research
collection DOAJ
language English
format Article
sources DOAJ
author John Anderson
Donald S. Levy
William Lumry
Patricia Koochaki
Sally Lanar
H. Henry Li
spellingShingle John Anderson
Donald S. Levy
William Lumry
Patricia Koochaki
Sally Lanar
H. Henry Li
Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
Allergy, Asthma & Clinical Immunology
Subcutaneous C1-inhibitor
Hereditary angioedema
Health-related quality of life
Productivity
HAEGARDA
Qualitative research
author_facet John Anderson
Donald S. Levy
William Lumry
Patricia Koochaki
Sally Lanar
H. Henry Li
author_sort John Anderson
title Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
title_short Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
title_full Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
title_fullStr Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
title_full_unstemmed Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy
title_sort letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous c1 inhibitor replacement therapy
publisher BMC
series Allergy, Asthma & Clinical Immunology
issn 1710-1492
publishDate 2021-06-01
description Abstract Background While many studies of effective hereditary angioedema (HAE) therapy have demonstrated improved health-related quality of life (HRQoL) using validated instruments, specific reasons behind the improved scores have never been investigated using qualitative methods. A non-interventional, qualitative research study was designed to investigate the reasons for improvements in HRQoL while using effective prophylaxis, in this case subcutaneous C1INH (C1INH[SC]) replacement therapy. Methods Adult patients with HAE-C1INH type 1 or 2 who had been using C1INH(SC) for ≥ 3 consecutive months were recruited through four HAE specialty practices in the US to participate in a 60-min phone interview performed by a trained qualitative research specialist (ICON plc) using a semi-structured interview guide with open-ended questions developed with the Angioedema Quality of Life (AE-QoL) items in mind. Interview transcripts were analyzed using thematic analysis methods to identify concepts (specific symptoms/impacts) and themes (higher-level categories grouping related concepts). A cross-mapping exercise was performed between interview-identified concepts and items included in the AE-QoL. Results Fourteen patients were interviewed and included in the analysis (age range, 28–82 years [mean 47.5 years]; 64% female; 93% white). In 10 interviews, patients mentioned having no or nearly no HAE attacks, no longer feeling limited by HAE, less HAE-related anxiety/worry and depression, an improved ability to travel, fewer emergency room/hospital visits, and ease of administration of C1INH(SC), including not requiring assistance from others. Other commonly expressed concepts included: increased feelings of confidence, independence, optimism, and normalcy; less absence from work/school; better productivity; improved sleep and energy; healthier family relationships; and improved cognition. While all AE-QoL items emerged from patient interviews, a number of identified concepts were not addressed by the AE-QoL, including sensitivity to various potential attack-triggers (e.g., stress/anxiety, sports), attack frequency, not having to cancel social plans, improvements in ability to perform day-to-day tasks, and a lower burden from medical visits. Conclusions From these interviews, a large number of common themes and concepts emerged: a greater sense of freedom and normalcy, increased productivity, and improved interpersonal relationships while using convenient and effective prophylaxis. These findings provide insights into real-world experiences and the many facets of HRQoL that are important to patients with HAE-C1INH.
topic Subcutaneous C1-inhibitor
Hereditary angioedema
Health-related quality of life
Productivity
HAEGARDA
Qualitative research
url https://doi.org/10.1186/s13223-021-00550-5
work_keys_str_mv AT johnanderson lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy
AT donaldslevy lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy
AT williamlumry lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy
AT patriciakoochaki lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy
AT sallylanar lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy
AT hhenryli lettingthepatientsspeakanindepthqualitativeresearchbasedinvestigationoffactorsrelevanttohealthrelatedqualityoflifeinrealworldpatientswithhereditaryangioedemausingsubcutaneousc1inhibitorreplacementtherapy
_version_ 1721319872539918336